BDNF rs 6265 polymorphism and COMT rs 4680 polymorphism in deficit schizophrenia in Polish sample

Pharmacological Reports

Volumn 65, Issue 5, 2013, Pages 1185-1193

  Peka Wysiecka, Justyna ^a   Wroñski, Micha ^a   Jasiewicz, Andrzej ^a   Grzywacz, Anna ^a   Tybura, Piotr ^a   Kucharska Mazur, Jolanta ^a   Bieñkowski, Przemysaw ^b   Samochowiec, Jerzy ^a  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

^b INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Poland)

Author keywords

BDNF; COMT; Deficit schizophrenia; Gene polymorphism; Nondeficit schizophrenia

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CATECHOL METHYLTRANSFERASE;

ADULT; ARTICLE; BRAIN DERIVED NEUROTROPHIC FACTOR GENE; CATECHOL O METHYLTRANSFERASE GENE; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENOTYPE; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; NEGATIVE SYNDROME; POLAND; SCHIZOPHRENIA;

ADULT; BRAIN-DERIVED NEUROTROPHIC FACTOR; CASE-CONTROL STUDIES; CATECHOL O-METHYLTRANSFERASE; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; MALE; MIDDLE AGED; PHENOTYPE; POLAND; POLYMORPHISM, GENETIC; RISK FACTORS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 84894154043     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(13)71476-2     Document Type: Article

References (54)

1. Amador X, Kirkpatrick B, Buchanan R, Carpenter W, Lynn M, Yale Scott A: Stability of the diagnosis of deficit syndrome in schizophrenia. Am J Psychiatry, 1999, 156, 637-639. (Pubitemid 29162989)
2. Angelucci F, Brenè S, Mathé A: BDNF in schizophrenia, depression and corresponding animal models. Mol Psychiatry, 2005, 10, 345-352.
3. Autry A, Monteggia L: Brain-derived neurotrophic factor and neuropsychiatric disorders. Pharmacol Rev, 2012, 64, 238-258.
4. Badner J, Gershon E: Meta-analysis of whole-genome linkage scans of bipolar disorder and schizophrenia. Mol Psychiatry, 2002, 7, 405-411. (Pubitemid 34499362)
5. Basta-Kaim A, Szczêsny E, Leoekiewicz M, Gombik K, OElusarczyk J, Budziszewska B, Regulska M et al.: Maternal immune activation leads to age-related behavioral and immunological changes in male rat offspring -the effect of antipsychotic drugs. Pharmacol Rep, 2012, 64, 1400-1410.
6. Bilder R, Volavka J, Czobor P, Malhotra A, Kennedy J, Ni X, Goldman R: Neurocognitive correlates of the COMT Val(158)Met polymorphism in chronic schizophrenia. Biol Psychiatry, 2002, 52, 701-707.
7. Bilder R, Volavka J, Lachman H, Grace A: The catechol-O-methyltransferase polymorphism: relations to the tonic-phasic dopamine hypothesis and neuropsychiatric phenotypes. Neuropsychopharmacology, 2004, 11, 1943-1961. (Pubitemid 39486546)
8. Burda K, Czubak A, Kus K, Nowakowska E, Ratajczak P, Zin J: Influence of aripiprazole on the antidepressant, anxiolytic and cognitive functions of rats. Pharmacol Rep, 2011, 63, 898-907.
9. Carpenter W, Heinrichs D, Wagman AI: Deficit and nondeficit forms of schizophrenia: the concept. Am J Psychiatry, 1988, 145, 578-583.
10. Chen X, Wang X, O'Neill A, Walsh D, Kendler K: Variants in the catechol-O-methyltransferase (COMT) gene are associated with schizophrenia in Irish highdensity families. Mol Psychiatry, 2004, 9, 962-967. (Pubitemid 39381960)
11. Cohen A, Brown L, Minor K: The psychiatric symptomatology of deficit schizophrenia: A meta-analysis. Schizophr Res, 2010, 118, 122-127.
12. Cohen A, Saperstein A, Gold J: Neuropsychology of the deficit syndrome: new data and meta-analysis of findings to date. Schizophr Bull, 2007, 33, 1201-1212. (Pubitemid 47347909)
13. Egan M, Goldberg T, Kolachana B, Callicott J, Mazzanti C, Straub R, Goldman D, Weinberger D: Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci USA, 2001, 12, 6917-6922. (Pubitemid 32538317)
14. Egan M, Kojima M, Callicott J, Goldberg T, Kolachana B, Bertolino A, Zaitsev E, Gold B: The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell, 2003, 112, 257-269. (Pubitemid 36144114)
15. Fenton W, McGlashan T: Antecedents, symptom progression, and long-term outcome of the deficit syndrome in schizophrenia. Am J Psychiatry, 1994, 151, 351-356. (Pubitemid 24081452)
16. Fenton W, McGlashan T: Testing systems for assessment of negative symptoms in schizophrenia. Arch Gen Psychiatry, 1992, 3, 179-184.
17. Galderisi S, Maj M, Kirkpatrick B, Piccardi P, Mucci A, Invernizzi G, Rossi A, Pini S: Catechol-O-methyltransferase Val 158 Met polymorphism in schizophrenia: associations with cognitive and motor impairment. Neuropsychobiology, 2005, 52, 83-89. (Pubitemid 41160325)
18. Galderisi S, Maj M, Kirkpatrick B, Piccardi P, Mucci A, Invernizzi G, Rossi A, Pini S: COMT Val (158) Met and BDNF C (270) T polymorphisms in schizophrenia: a case-control study. Schizophr Res, 2005, 73, 27-30. (Pubitemid 39574675)
19. Grzywacz A, Samochowiec A, Ciechanowicz A, Samochowiec J: Family-based study of brain-derived neurotrophic factor (BDNF) gene polymorphism in alcohol dependence. Pharmacol Rep, 2010, 62, 938-941.
20. Guillin O, Demily C, Thibaut F: Brain-derived neurotrophic factor in schizophrenia and its relation with dopamine. Int Rev Neurobiol, 2007, 78, 377-395.
21. Herken H, Erdal M: Catechol-O-methyltransferase gene polymorphism in schizophrenia: evidence for association between symptomatology and prognosis. Psychiatr Genet, 2001, 1, 105-109. (Pubitemid 32686191)
22. Hosák L: Role of the COMT gene Val158Met polymorphism in mental disorders: a review. Eur Psychiatry, 2007, 22, 276-281. (Pubitemid 47088199)
23. Jarema M, Kiejna A, Landowski J, Meder J, Rabe-Jabonska J, Rybakowski J: Pharmacological standards. Schizophrenia treatment. Psychiatr Pol, 2006, 40, 1171-1205.
24. Kay S, Fiszbein A, Opler L: The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull, 1987, 13, 261-276. (Pubitemid 18039085)
25. Kirkpatrick B, Buchanan R, McKenney P, Alphs L, Carpenter W: The schedule for the deficit syndrome: An instrument for research in schizophrenia. Psychiatry Res, 1989, 30, 119-124.
26. Kirkpatrick B, Buchanan R, Ross D, Carpenter W: A separate disease within the syndrome of schizophrenia. Arch Gen Psychiatry, 2001, 2, 165-171. (Pubitemid 32142754)
27. Kirkpatrick B, Fenton W, Carpenter Jr. W, Marder S: The NIMHMATRICS consensus statement on negative symptoms. Schizophr Bull, 2006, 32, 214-219.
28. Lachman H, Papolos D, Saito T, Yu Y, Szumlanski C, Weinshilboum R: Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics, 1996, 6, 243-250. (Pubitemid 26226317)
29. Li W, Kou C, Yu Y, Sun S, Zhang X, Kosten T, Zhang X: Association of catechol-O-methyltransferase gene polymorphisms with schizophrenia and negative symptoms in a Chinese population. Am J Med Genet B Neuropsychiatr Genet, 2012, 4, 370-375.
30. Liao S, Lin S, Liu C, Hsieh M, Hwang T, Liu S, Guo S et al.: Genetic variants in COMT and neurocognitive impairment in families of patients with schizophrenia. Genes Brain Behav, 2009, 2, 228-237.
31. Lipsky R, Marini A: Brain-derived neurotrophic factor in neuronal survival and behavior-related plasticity. Ann NY Acad Sci, 2007, 122, 130-143. (Pubitemid 350249544)
32. Mahmood D, Khanam R, Pillai K, Akhtar M: Protective effects of histamine H3-receptor ligands in schizophrenic behaviors in experimental models. Pharmacol Rep, 2012, 64, 191-204.
33. Maisonpierre P, Le Beau M, Espinosa R 3rd, Ip N, Belluscio L, de la Monte S, Squinto S et al.: Human and rat brain-derived neurotrophic factor and neurotrophin-3: gene structures, distributions, and chromosomal localizations. Genomics, 1991, 10, 558-568.
34. McGuffin P, Farmer A, Harvey I: A polydiagnostic application of operational criteria in studies of psychotic illness. Development and reliability of the OPCRIT system. Arch Gen Psychiatry, 1991, 48, 764-770.
35. Munafò M, Bowes L, Clark T, Flint J: Lack of association of the COMT (Val158/108 Met) gene and schizophrenia: a meta-analysis of case-control studies. Mol Psychiatry, 2005, 10, 765-770. (Pubitemid 41129049)
36. Naoe Y, Shinkai T, Hori H, Fukunaka Y, Utsunomiya K, Sakata S, Matsumoto C, Shimizu K: No association between the brain-derived neurotrophic factor (BDNF) Val66Met polymorphism and schizophrenia in Asian populations: Evidence from a case-control study and meta-analysis. Neurosci Lett, 2007, 415, 108-112. (Pubitemid 46402897)
37. Neves-Pereira M, Cheung J, Pasdar A, Zhang F, Breen G, Yates P, Sinclair M, Crombie C: BDNF gene is a risk factor for schizophrenia in a Scottish population. Mol Psychiatry, 2005, 10, 208-212. (Pubitemid 40188515)
38. Noto C, Gadelha A, Belangero S, Smith M, de Aguiar B, Panizzuti B, Mari J de J et al.: Association of biomarkers and depressive symptoms in schizophrenia. Neurosci Lett, 2011, 505, 282-285.
39. Peka-Wysiecka J, Ziêtek J, Grzywacz A, Kucharska-Mazur J, Bienkowski P, Samochowiec J: Association of genetic polymorphisms with personality profile in individuals without psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry, 2012, 39, 40-46.
40. Puyñski S, Wciórka J: International Statistical Classification of Diseases and Related Health Problems, 10 Revision (Polish). IPiN, Kraków-Warszawa, Vesalius, 1997.
41. Rao V, Carvalho A, Trevisan M, Andrade G, Nobre-Júnior H, Moraes MO, Magalhães HI et al.: Mangiferin ameliorates 6-hydroxydopamine-induced cytotoxicity and oxidative stress in ketamine model of schizophrenia. Pharmacol Rep, 2012, 64, 848-856.
42. Ratajczak P, Kus K, Jarmuszkiewicz Z, Woniak A, Cichocki M, Nowakowska E: Influence of aripiprazole and olanzapine on behavioral dysfunctions of adolescent rats exposed to stress in perinatal period. Pharmacol Rep, 2013, 65, 30-43.
43. Rogó Z: Effect of co-treatment with mirtazapine and risperidone in animal models of the positive symptoms of schizophrenia in mice. Pharmacol Rep, 2012, 64, 1567-1572.
44. Ross D, Kirkpatrick B, Karkowski L, Straub R, MacLean C, O'Neill F, Compton Aet al.: Sibling correlation of deficit syndrome in the Irish study of high-density schizophrenia families. Am J Psychiatry, 2000, 7, 1071-1076. (Pubitemid 30432486)
45. Sheehan D, Lecrubier Y, Sheehan K, Amorim P, Janavs J, Weiller E, Hergueta T et al.: The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry, 1998, 20, 22-33. (Pubitemid 29001829)
46. Spalletta G, Morris D, Angelucci F, Rubino I, Spoletini I, Bria P, Martinotti G, Siracusano A: BDNF Val66Met polymorphism is associated with aggressive behavior in schizophrenia. Eur Psychiatry, 2010, 25, 311-313.
47. Tandon R: The nosology of schizophrenia: Toward DSM-5 and ICD-11. Psychiatr Clin North Am, 2012, 35, 557-569.
48. Tek C, Kirkpatrick B, Buchanan R: A five-year followup study of deficit and nondeficit schizophrenia. Schizophr Res, 2001, 3, 253-260. (Pubitemid 32453226)
49. Tovilla-Zárate C, Medellín BC, Fresán A, López-Narváez L, Castro TB, Juárez Rojop I, Ramírez-Bello J et al.: No association between catechol-o- methyltransferase Val108/158Met polymorphism and schizophrenia or its clinical symptomatology in a Mexican population. Mol Biol Rep, 2013, 40, 2053-2058.
50. Tybura P, Mak M, Samochowiec A, Peka-Wysiecka J, Grzywacz A, Grochans E, Zaremba-Pechmann L, Samochowiec J: The influence of antipsychotic therapy on the cognitive functions of schizophrenic patients. Psychiatr Pol, 2013, 4, 567-578.
51. Tybura P, Samochowiec A, Beszlej A, Grzywacz A, Mak M, Frydecka D, Bieñkowski P et al.: Some dopaminergic genes polymorphisms are not associated with response to antipsychotic drugs in schizophrenic patients. Pharmacol Rep, 2012, 64, 528-535.
52. Wang Y, Fang Y, Shen Y, Xu Q: Analysis of association between the catechol-O-methyltransferase (COMT) gene and negative symptoms in chronic schizophrenia. Psychiatry Res, 2010, 179, 147-150.
53. Wonodi I, Mitchell B, Stine O, Hong L, Elliott A, Kirkpatrick B, Carpenter W Jr. et al.: Lack of association between COMT gene and deficit/nondeficit schizophrenia. Behav Brain Funct, 2006, 2, 42.
54. Zhang F, Liu C, Chen Y, Wang L, Lu T, Yan H, Ruan Y et al.: No association of catechol-O-methyltransferase polymorphisms with schizophrenia in the Han Chinese population. Genet TestMol Biomarkers, 2012, 16, 1138-1141.